




The relative strengths and weaknesses of Relmada Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Relmada Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 133% points. The greatest weakness of Relmada Therapeutics INC is the variable Net Income, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 274%, being 61% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	97,509
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,195
Liabilities, Non-Current	0
Other Assets	43
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	4,911
Other Revenues	0
Property and Equipment	0
Research and Development	54,807
Selling, General and Administrative Expense	48,895

Output Variable	Value in 1000 USD
Assets	97,552
Liabilities	12,195
Expenses	103,702
Revenues	0
Stockholders Equity	85,357
Net Income	-98,792
Comprehensive Net Income	-98,792
BaseVar	109,180
ECR before Limited Liability	159%
Economic Capital Ratio	274%